{"id":"NCT01034111","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)","officialTitle":"An Open-label Study to Assess the Safety and Tolerability of JANUVIA (Sitagliptin) in 30 Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03-01","primaryCompletion":"2010-10-04","completion":"2010-10-04","firstPosted":"2009-12-17","resultsPosted":"2011-11-07","lastUpdate":"2017-05-30"},"enrollment":30,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Sitagliptin phosphate","otherNames":["MK-0431","Januvia"]},{"type":"DRUG","name":"Metformin","otherNames":["Glucophage"]}],"arms":[{"label":"Sitagliptin","type":"EXPERIMENTAL"}],"summary":"This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin monotherapy.","primaryOutcome":{"measure":"Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment","timeFrame":"4 weeks","effectByArm":[{"arm":"Sitagliptin","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Hepatic Enzyme Increased","Decreased Appetite"]}}